OLIPASS Past Earnings Performance
Past criteria checks 0/6
OLIPASS has been growing earnings at an average annual rate of 20.7%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 23.3% per year.
Key information
20.7%
Earnings growth rate
30.5%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 23.3% |
| Return on equity | -503.1% |
| Net Margin | -318.4% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How OLIPASS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 5,251 | -16,717 | 5,963 | 14,005 |
| 30 Jun 23 | 3,635 | -18,952 | 6,585 | 13,875 |
| 31 Mar 23 | 2,128 | -23,381 | 7,526 | 15,649 |
| 31 Dec 22 | 2,296 | -24,168 | 8,998 | 15,030 |
| 30 Sep 22 | 1,806 | -25,243 | 9,858 | 14,914 |
| 30 Jun 22 | 1,782 | -25,760 | 10,322 | 14,941 |
| 31 Mar 22 | 1,683 | -24,296 | 10,331 | 13,391 |
| 31 Dec 21 | 852 | -25,135 | 9,329 | 14,347 |
| 30 Sep 21 | 856 | -22,908 | 8,857 | 13,500 |
| 30 Jun 21 | 893 | -23,036 | 8,076 | 14,182 |
| 31 Mar 21 | 1,539 | -24,880 | 8,981 | 14,886 |
| 31 Dec 20 | 2,861 | -24,183 | 10,423 | 13,127 |
| 30 Sep 20 | 3,512 | -47,852 | 12,044 | 12,173 |
| 30 Jun 20 | 3,614 | -50,249 | 13,187 | 11,282 |
| 31 Mar 20 | 2,993 | -46,850 | 12,249 | 9,752 |
| 31 Dec 19 | 1,705 | -45,640 | 10,942 | 9,693 |
| 30 Sep 19 | 1,019 | -25,663 | 9,625 | 10,062 |
Quality Earnings: A244460 is currently unprofitable.
Growing Profit Margin: A244460 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A244460 is unprofitable, but has reduced losses over the past 5 years at a rate of 20.7% per year.
Accelerating Growth: Unable to compare A244460's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A244460 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A244460 has a negative Return on Equity (-503.14%), as it is currently unprofitable.